Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential?

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 1, 1997, Pages 220-227

  Carlsson, Leif ^a   Amos, Gregory J ^a   Andersson, Birgit ^a   Drews, Lissen ^a   Duker, Göran ^a   Wadstedt, Gunilla ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; CISAPRIDE; MOSAPRIDE CITRATE; PROKINETIC AGENT; PROPRANOLOL; SOTALOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GASTROINTESTINAL MOTILITY; GUINEA PIG; HEART MUSCLE POTENTIAL; HEART VENTRICLE FIBRILLATION; INTRAVENOUS DRUG ADMINISTRATION; LONG QT SYNDROME; NONHUMAN; PRIORITY JOURNAL; PURKINJE FIBER; QT INTERVAL; RABBIT; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; ARRHYTHMIA; BENZAMIDES; CISAPRIDE; GUINEA PIGS; HEART; LONG QT SYNDROME; MALE; MORPHOLINES; PIPERIDINES; PURKINJE FIBERS; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030801806     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. κ blocking drugs, UK-68,798 (dofetilide) and E-4031. J. Cardiovasc. Pharmacol. 27: 861-867, 1993.
2. ADRAC on cisapride, acyclovir, SSRIs. SCRIP. 2158: 27, 1996.
3. AHMAD, S. R. AND WOLFE, S. M.: Cisapride and torsades de pointes. Lancet. 345: 508, 1995.
4. ANTZELEWITCH, C., SICOURI, S., LITOVSKY, S. H., LUKAS, A., KRISHNAN, S. C., DI DIEGO, J. M., GINTANT, G. A. AND LIU, D. W.: Heterogeneity within the ventricular wall-Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ. Res. 69: 1427-1449, 1991.
5. AXENBORG, J. E. AND HIRSCH, L: A PC-based on-line system for physiological in vivo and in vitro experiments. Comput. Methods Programs Biomed. 41: 55-67, 1993.
6. BRAN, S., MURRAY, W. A., HIRSCH, I. B. AND PALMER, J. P.: Long QT syndrome during high-dose cisapride. Arch. Intern. Med. 155: 765-768, 1995.
7. BRIEJER, M. R., AKKERMANS, L. M. A. AND SCHUURKES, J. A. J.: Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol. Rev. 47: 631-651, 1995.
8. BUCHANAN, L. V., KABELL, G., BRUNDEN, M. N. AND GIBSON, J. K.: Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J. Cardiovasc. Pharmacol. 22: 540-549, 1993.
9. CARLSSON, L., ABRAHAMSSON, C., ANDERSSON, B., DUKER, G. AND SCHILLER-LINHARDT, G.: Proarrhythmic effects of the class III antiarrhythmic agent almokalant: Importance of infusion rate, QT dispersion and early afterde-polarisations. Cardiovasc. Res. 27: 2186-2193, 1993.
10. CARLSSON, L., ALMGREN, O. AND DUKER G.: QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit-Etiology and interventions. J. Cardiovasc. Pharmacol. 16: 276-285, 1990.
11. + current in cardiac myocytes by dofetilide. J. Pharmacol. Exp. Ther. 262: 809-817, 1992.
12. 4 receptor antagonist: Comparison to cisapride and RS23597-190. J. Pharmacol . Exp. Ther. 277: 97-104, 1996.
13. COLATSKY, T. J. AND ARGENTIERI, T. M.: Potassium channel blockers as antiarrhythmic drugs. Drug Dev. Res. 33: 235-249, 1994.
14. CROSS, P. E., ARROWSMITH, J. E., THOMAS, G. N., GWILT, M., BURGES, R. A. AND HIGGINS, A. J.: Selective class III antiarrhythmic agents. 1. Bis (arylalkyl) amines. J. Med. Chem. 33: 1151-1155, 1990.
15. FAZEKAS, T., CARLSSON, L., SCHERLAG, B. J., MABO, P., POTY, H., PALMER, M., PATTERSON, E., DARRELL BERLIN, K., GARRISON, G. L. AND LAZZARA, R.: Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG-V-13, in the guinea-pig, rabbit and canine heart. J. Cardiovasc. Pharmacol. 28: 182-191, 1996.
16. HUI, W. K. K., MITCHELL, L. B., KAVANAGH, K. M., GILLIS, A. M., WYSE, D. G., MANYARI, D. E. AND DUFF, H. J.: Melperone: Electrophysiological and antiarrhythmic activity in humans. J. Cardiovasc. Pharmacol. 15: 144-149, 1990.
17. JACKMAN, W. M., FRIDAY, K. J., ANDERSON, J. L., ALIOT, E. M., CLARK, M. AND LAZZARA, R.: The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog. Cardiovasc. Dis. 31: 115-172, 1988.
18. JOHNSON, R. E., SILVER, P. J., BECKER, R., BIRSNER, N. C., BOHNET, E. A., BRIGGS, G. M., BUSACCA, C. A., CANNIFF, P., CARABATEAS, P. M., CHADWICK, C. C., D'AMBRA, T., DUNDORE, R. L., DUNG, J. S., EZRIN, A. M., GORCZYCA, W., HABEEB, P. G., KRAFTE, P. H. D. S., PILLING, G. M., O'CONNOR, B., SAINDANE, M. T., SCHLEGEL, D. C., STANKUS, G. P., SWESTOCK, J. AND VOLBERG, W. A.: 4,5-Dihydro-3(methanesulfonamidophenyl)-1-phenyl-1H-2,4-benzodiazepines: A novel class III antiarrhythmic agents. J. Med. Chem. 38: 2551-2556, 1995.
19. KARASAWA, T., YOSHIDA, N., FURUKAWA, K., OMOYA, H. AND ITO, T.: Comparison of gastrokinetic effects of AS-4370, cisapride and BRL24924 (abstract). Eur. J. Pharmacol. 183: 2181, 1990.
20. LEWIN, M. B., BRYANT, R. M., FENRICH, A. L. AND GRIFKA, R. G.: Cisapride-induced long QT interval. J. Pediatr. 128: 279-281, 1996.
21. MACCALLUM, R. W.: Cisapride: A new class of prokinetic agent. Am. J. Gastroenterol. 86: 135-149, 1991.
22. MORGAN JR, T. K. AND SULLIVAN, M. E.: An overview of class III electrophysiological agents: A new generation of antiarrhythmic therapy. In Progress in Medicinal Chemistry, ed. by G. P. Ellis and D. K. Luscombe, pp. 65-108, Elsevier Science Publishers B. V, Amsterdam, 1992.
23. ONAT, F., YEGEN, B., BERKMAN, K. AND OKTAY S.: The hypotensive effect of cisapride in rat. Gen. Pharmacol. 25: 1253-1256, 1994.
24. PUISIEUX, F. L., ADAMANTIDIS, M. M., DUMOTIER, B. M. AND DUPUIS, B. A.: Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br. J. Pharmacol. 117: 1377-1379, 1996.
25. RODEN, D. M.: Current status of class III antiarrhythmic drug therapy. Am. J. Cardiol. 72: 44B-49B, 1993.
26. SCHUURKES, J. A. J., VAN NUETEN, J. M., VAN DAELE, P. G. H., REYNTJENS, A. J. AND JANSSEN, P. A. J.: Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig. J. Pharmacol. Exp. Ther. 234: 775-783, 1985.
27. SJÖVALL, H. AND ABRAHAMSSON, H.: Mosapride enhances human esophageal motility. Gastroenterology 110: A760, 1996.
28. SUYAMA, T., TOKUBAYASHI, F., OMATSU, Y., KAWAI, T., TATEISHI, H., TAKAGI, A., MIZUTA, K. AND MIYOSHI, A.: Accelerating effect of AS-4370 (mosapride) on gastric emptying time (double sampling test method) and its clinical efficacy on chronic gastritis accompanied by epigastric symptoms. Jpn. Arch. Intern. Med. 40: 175-183, 1993.
29. TAN, H. L., HOU, C. J. Y., LAUER, M. R. AND SUNG, R. J.: Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann. Intern. Med. 122: 701-714, 1995.
30. Warning on cisapride interactions. SCRIP. 2123: 21, 1996.
31. WISEMAN, L. R. AND FAULDS, D.: Cisapride: An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 47: 116-152, 1994.
32. WYSOWSKI, D. K. AND BACSANYI, J.: Cisapride and fatal arrhythmia. N. Engl. J. Med. 335: 290-291, 1996.
33. YOSHIDA, N., OMOYA, H., KATO, S. AND ITO, T.: Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneim-Forsch/Drug Res. 43: 1078-1083, 1993.